The Chronic Lymphocytic Leukemia Channel is supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwCLL 2023 | Resistance to non-covalent BTKi’s
In this video, Varsha Gandhi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, outlines the investigation, undertaken at the MD Anderson Cancer Centre, into resistance to non-covalent BTK inhibitors (BTKi’s), namely pirtobrutinib, in patients with chronic lymphocytic leukemia (CLL). Dr Gandhi highlights the driver mutations commonly observed in these patients before and during treatment. This interview was recorded at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
